These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 870162)

  • 1. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease.
    Diggs CH; Wiernik PH; Levi JA; Kvols LK
    Cancer; 1977 May; 39(5):1949-54. PubMed ID: 870162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.
    Bloomfield CD; Weiss RB; Fortuny I; Vosika G; Kennedy BJ
    Cancer; 1976 Jul; 38(1):42-8. PubMed ID: 947533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
    Durant JR; Bartolucci A; Gams RA; Dorfman RF; Velez-Garcia E
    Cancer Treat Rep; 1976 Jun; 60(6):781-7. PubMed ID: 782700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease.
    Cooper MR; Pajak TF; Nissen NI; Stutzman L; Brunner K; Cuttner J; Falkson G; Grunwald H; Bank A; Leone L; Seligman BR; Silver RT; Weiss RB; Haurani F; Blom J; Spurr CL; Glidewell OJ; Gottlieb AJ; Holland JF
    Cancer; 1980 Aug; 46(4):654-62. PubMed ID: 7397630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone.
    Gibbs GE; Peterson BA; Kennedy BJ; Vosika G; Bloomfield CD
    Arch Intern Med; 1981 Jun; 141(7):897-900. PubMed ID: 7235809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of Hodgkin's disease in children.
    Kolygin BA
    Cancer; 1976 Oct; 38(4):1494-7. PubMed ID: 991072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy of advanced Hodgkin's disease. A review.
    Goldsmith MA; Carter SK
    Cancer; 1974 Jan; 33(1):1-8. PubMed ID: 4129559
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
    Host H; Abrahamsen AF
    Scand J Haematol; 1973; 10(3):170-6. PubMed ID: 4588616
    [No Abstract]   [Full Text] [Related]  

  • 10. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
    Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
    J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.
    Porzig KJ; Portlock CS; Robertson A; Rosenberg SA
    Cancer; 1978 May; 41(5):1670-5. PubMed ID: 77180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].
    Osieka R; Bruntsch U; Gallmeier WM; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1976 Aug; 101(32):1177-82. PubMed ID: 59661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease.
    Pavlovsky S; Santarelli MT; Muriel FS; Fernández I; Garcia I; Schwartz L; Montero C; Sanahuja FL; Magnasco H; Costa A
    Ann Oncol; 1992 Jul; 3(7):533-7. PubMed ID: 1498073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of two chemotherapy protocols in Hodgkin's disease.
    Pavlovsky S; Morgenfeld M; Somoza N; Magnasco J; Sackmann Muriel F; Cavagnaro F; Suárez A; Barros CA; Saslavsky J; Garay G; Palau M; Besuschio SC
    Medicina (B Aires); 1981; 41 Suppl():15-21. PubMed ID: 6896551
    [No Abstract]   [Full Text] [Related]  

  • 17. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.
    Santoro A; Viviani S; Valagussa P; Bonfante V; Bonadonna G
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):23-6. PubMed ID: 2420012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.
    Kurnick JE; White M; Ware DE; Robinson WA
    Cancer Chemother Rep; 1975; 59(6):1147-50. PubMed ID: 56989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.